{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:21:01Z","timestamp":1783178461927,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004233","name":"Universitat Polit\u00e8cnica de Val\u00e8ncia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019161","name":"Fundaci\u00f3n Universia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003451","name":"Euskal Herriko Unibertsitatea","doi-asserted-by":"publisher","award":["PPG17\/65"],"award-info":[{"award-number":["PPG17\/65"]}],"id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003451","name":"Euskal Herriko Unibertsitatea","doi-asserted-by":"publisher","award":["GIU17\/032"],"award-info":[{"award-number":["GIU17\/032"]}],"id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.eimc.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T11:21:59Z","timestamp":1555500119000},"page":"626-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK\/PD analysis: an 18-year surveillance study"],"prefix":"10.1016","volume":"37","author":[{"given":"Ana","family":"Valero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rodr\u00edguez-Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Canut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"\u00c1ngeles Solin\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2019.02.009_bib0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3390\/antibiotics4040643","article-title":"Utilizing Monte Carlo simulations to optimize institutional empiric antipseudomonal therapy","volume":"4","author":"Tennant","year":"2015","journal-title":"Antibiotics"},{"key":"10.1016\/j.eimc.2019.02.009_bib0160","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2019.02.009_bib0165","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10096-018-3292-9","article-title":"Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007\u20132015)","volume":"37","author":"De Angelis","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2019.02.009_bib0170","series-title":"Global action plan on antimicrobial resistance","author":"World Health Organisation (WHO)","year":"2015"},{"key":"10.1016\/j.eimc.2019.02.009_bib0175","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1128\/AAC.48.12.4606-4610.2004","article-title":"National surveillance of sntimicrobial resistance in Pseudomonas aeruginosa isolates obtained from Intensive Care Unit patients from 1993 to 2002","volume":"48","author":"Obritsch","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0180","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000437252","article-title":"Susceptibility of 2,252 Pseudomonas aeruginosa clinical isolates over 4 years to 9 antimicrobials ina tertiary Greek hospital","volume":"60","author":"Maraki","year":"2014","journal-title":"Chemotherapy"},{"key":"10.1016\/j.eimc.2019.02.009_bib0185","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1017\/S0950268809990100","article-title":"Surveillance for antimicrobial resistant organisms: potential souces and magnitude of bias","volume":"137","author":"Rempel","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.eimc.2019.02.009_bib0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"Asin-Prieto","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0195","article-title":"Pharmacokinetic\/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients","author":"Valero","year":"2018","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2019.02.009_bib0200","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.eimc.2019.02.009_bib0205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u201cbug and drug\u201d","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.eimc.2019.02.009_bib0210","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0215","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.clinthera.2010.04.003","article-title":"Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States","volume":"32","author":"Koomanachai","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.eimc.2019.02.009_bib0220","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/AAC.36.7.1382","article-title":"Lack of pharmacokinetic interaction between cefepime and amikacin in humans","volume":"36","author":"Barbhaiya","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0225","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/dkm536","article-title":"Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodinamic models with Monte Carlo simulation","volume":"61","author":"Frei","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.eimc.2019.02.009_bib0230","doi-asserted-by":"crossref","first-page":"i67","DOI":"10.1093\/jac\/dkt028","article-title":"Canadian Antimicrobial Resistance Alliance Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD)","volume":"68","author":"Zelenitsky","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0235","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jac\/dkg403","article-title":"Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis","volume":"52","author":"Zelenitsky","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0240","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.31.2.264","article-title":"Pharmacokinetics of cefoperazone and tobramycin alone and in combination","volume":"31","author":"Guglielmo","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0245","series-title":"Analysis and presentation of cumulative antimicrobial susceptibility test data","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.eimc.2019.02.009_bib0250","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0255","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10096-015-2568-6","article-title":"Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum \u03b2-lactamases","volume":"35","author":"Isla","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2019.02.009_bib0260","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1086\/514747","article-title":"Impact of use of multiple antimicrobial on changes in susceptibility of gram negative aerobes","volume":"28","author":"Friedrich","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2019.02.009_bib0265","first-page":"78","article-title":"Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish society of chemotherapy","volume":"31","author":"Mensa","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.eimc.2019.02.009_bib0270","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1097\/CCM.0b013e3182923622","article-title":"Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU: the Spanish experience","volume":"41","author":"Palomar","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.eimc.2019.02.009_bib0275","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.medin.2013.12.007","article-title":"Sociedad Espa\u00f1ola de Medicina Intensiva; Sociedad Espa\u00f1ola de Enfermer\u00eda Intensiva Guidelines for the prevention of ventilator-associated pneumonia and their implementation. The Spanish \u201cZero-VAP\u201d bundle","volume":"38","author":"\u00c1lvarez Lerma","year":"2014","journal-title":"Med Intensiva"},{"key":"10.1016\/j.eimc.2019.02.009_bib0280","series-title":"Plan Nacional Frente a la Resistencia a los antibi\u00f3ticos 2014\u20132018","year":"2015"},{"issue":"1.","key":"10.1016\/j.eimc.2019.02.009_bib0285","first-page":"22.e1","article-title":"Programas de optimizaci\u00f3n de uso de antimicrobianos (PROA) en hospitales espa\u00f1oles: documento de consenso GEIH-SEIMC SEFH y SEMPSPH","volume":"30","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2019.02.009_bib0290","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1128\/AAC.01487-06","article-title":"Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organism","volume":"51","author":"Bhat","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.02.009_bib0295","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12941-017-0227-8","article-title":"Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study","volume":"16","author":"Su","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.eimc.2019.02.009_bib0300","series-title":"Clinical Breakpoints, bacteria (v 8.1)","author":"European Commitee of antimicrobial susceptibility testing (EUCAST)","year":"2018"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X19301454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X19301454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:55:34Z","timestamp":1777528534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X19301454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0213005X19301454"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2019.02.009","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK\/PD analysis: an 18-year surveillance study","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}